Recent studies in cancer immunotherapy have shown that low doses of antigen, rather than high doses, preferentially primed high avidity CD4+T cells, which in turn stimulated both antibody [8] responses and cytotoxic T cell responses effectively, instead of skewing the response towards one arm of the immune system [36]. Here, CD4 is linked to cancer.